GTHX News and Press, G1 Therapeutics Inc.

2024-07-01 08:25:52 ET More on G1 Therapeutics G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript G1 Therapeutics drops as breast cancer therapy fails in late-stage trial G...

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of...

2024-06-30 09:10:33 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead

2024-06-28 15:00:00 ET More on the markets S&P 500: Stay Invested, But Pay Attention To These Risks SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation S&P 500 H1 performance: Market cap vs. Equal weight Biden-Trump pre...

2024-06-25 08:00:05 ET Edward White from H.C. Wainwright issued a price target of $3.00 for GTHX on 2024-06-25 06:22:00. The adjusted price target was set to $3.00. At the time of the announcement, GTHX was trading at $2.22. GTHX currently trades -63.60% versus its 52 we...

2024-06-25 06:59:42 ET More on G1 Therapeutics G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript G1 Therapeutics slips after new breast cancer data for lead asset G1 Thera...

A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...

- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market - - G1 is Sufficiently Funded to Ac...

2024-05-28 14:34:16 ET More on G1 Therapeutics G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeu...

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient P...